OBSERVATIONAL STUDIES ARE IN THE EYE OF THE BEHOLDER
There is a critical gap in evidence regarding whether different treatment strategies early in relapsing multiple sclerosis prevent...
FUNDAMENTALS OF MS CARE – PART 2: DIAGNOSING THE DISEASE AND MANAGING SPECIFIC POPULATIONS
Sessions 1 and 2 of Fundamentals offers a multidisciplinary approach in the diagnosis and management of multiple sclerosis (MS). The...
CHOICES & CONTROVERSIES IN MS MANAGEMENT: A PRO/CON CASE-BASED DISCUSSION
This interactive case-based symposium will highlight contemporary controversies in MS disease management. Three debates will be moderated...
MRI INTERNATIONAL GUIDELINES
MRI is an invaluable tool for establishing an early diagnosis of MS and for monitoring patients disease course and response to treatment....
LATE BREAKING SCIENCE
Progress in understanding and treating multiple sclerosis evolves continuously and not always on a schedule aligned with scientific meeting...
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...